BioSpace News Archive

PharmaBlock (Stock code: 300725.SZSE) is a global, fully integrated CRDMO that offers innovative chemistry products and services throughout the pharmaceutical R&D process and commercial manufacturing

Biond Biologics Ltd. is excited to announce that our BND-35 program has been selected for presentation at the esteemed American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 5 - 10, 2024, in San Diego Convention Center, San Diego, CA, USA.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 23rd Annual Needham Virtual Healthcare Conference.

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful completion of its purchase of AL102 and related drug candidate AL101 from Ayala Pharmaceuticals, Inc.

MEI Pharma, Inc. (Nasdaq: MEIP) today reported initiation of enrollment in a 12-patient expansion cohort in the ongoing Phase 1 study evaluating voruciclib, an investigational selective oral cyclin-dependent kinase 9 (“CDK9”) inhibitor, in combination with venetoclax (Venclexta®), a B-cell lymphoma 2 (“BCL2”) inhibitor, in relapsed and refractory (“R/R”) acute myeloid leukemia (“AML”) patients.

Watchmaker Genomics, a supplier of innovative products for molecular analysis, announced the launch of the Watchmaker mRNA Library Prep Kit – designed to streamline and accelerate mRNA library preparation, offering both speed and sensitivity to the genomics community.

MAIA Biotechnology, Inc. announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 578,643 shares of common stock at a purchase price of $2.295 per share, in a private placement to accredited investors.

Ankyra Therapeutics and Jenga Biosciences are pleased to announce today an exclusive license agreement to develop and commercialize JEN-101 (formerly known as cANK-101).

Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI) today announced the online publication of the manuscript “Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models” in Nature Communications (“Springer-Nature”), an international journal publishing peer-reviewed research in all fields of science and technology.

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results.